Select Page

A single-site randomized controlled trial of partner navigation to HCV treatment for people who inject drugs: a study protocol for the You’re Empowered for Treatment Initiation (YETI) partner trial
“This trial will provide evidence of a new HCV treatment linkage intervention leveraging the support of primary injecting partners to initiate HCV treatment. If successful, the intervention could inform public health strategies and policies to address HCV in marginalized populations.”

Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
“Conclusion: Cirrhotic patients exhibited increased susceptibility to virological relapse, HCC, unfavorable prognosis, and liver disease progression following DAA treatment. Consequently, it is imperative to implement a rigorous monitoring protocol for all cirrhotic patients after DAA treatment.”

AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs
“The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs. The use of immunosuppressive drugs has increased significantly since 2013, according to data gathered via the National Health Interview Survey.”

Study: Contrast-Enhanced Ultrasound May Improve LI-RADS Assessment of High-Risk Indeterminate Liver Lesions
“For patients previously assessed with LI-RADS LR-4 and LR-M presentations based on MRI or CT findings, the use of contrast-enhanced ultrasound led to 30 percent of these patients having LR-5 assessments definitive for hepatocellular carcinoma.”

HCV-Positive Donor Kidneys Safe For Use in HCV-Negative Recipients, Study Finds
“Donor hepatitis C virus (HCV) positivity does not negatively impact 1-year rejection and mortality outcomes following renal transplantation in HCV-negative recipients, according to findings from a recent study.”

Study: Mid-Missouri overdose patients seldom tested for Hep C
“A recent analysis from the University of Missouri found that mid-Missourians visiting emergency room for opioid overdoses had high rates of hepatitis C positivity but low rates of being tested for the disease.”

Promising Results for Triplet Blockade Therapy in Unresectable Hepatocellular Carcinoma
“A novel phase II study investigating the triplet blockade of IL-27, PD-(L)1, and VEGF pathways in unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC) demonstrated encouraging antitumor activity and a manageable safety profile. Presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Daneng Li, MD, of the City of Hope National Comprehensive Cancer Center, the study highlights the potential of the first-in-class IL-27–targeting antibody, casdozokitug (casdozo), combined with atezolizumab (atezo) and bevacizumab (bev), as a promising treatment strategy.”

Student view: My experience with the Leadership in Medicine for the Underserved program
“Juan Jimenez is a third-year student at Michigan State University College of Human Medicine. As part of the Leadership in Medicine for the Underserved program, he recently completed an elective at Wellness Services in Flint, where he spent time learning about specialty HIV care and syringe service programs, and assisted staff in creating and distributing harm reduction kits for clients.”